The biology and future prospects of antivirulence therapies (original) (raw)

• Alekshun, M. N. & Levy, S. B. Molecular mechanisms of antibacterial multidrug resistance. Cell 128, 1037–1050 (2007).
  Article CAS PubMed Google Scholar
• Livermore, D. M. Minimising antibiotic resistance. Lancet Infect. Dis. 5, 450–459 (2005).
  Article PubMed Google Scholar
• Palumbi, S. R. Humans as the world's greatest evolutionary force. Science 293, 1786–1790 (2001).
  Article CAS PubMed Google Scholar
• Vicente, M. et al. The fallacies of hope: will we discover new antibiotics to combat pathogenic bacteria in time? FEMS Microbiol. Rev. 30, 841–852 (2006).
  Article CAS PubMed Google Scholar
• Levy, S. B. & Marshall, B. Antibacterial resistance worldwide: causes, challenges and responses. Nature Med. 10, S122–S129 (2004).
  Article CAS PubMed Google Scholar
• Crowley, P. J. & Martini, L. G. Formulation design: new drugs from old. Drug Discov. Today: Therapeutic Strategies 1, 537–542 (2004).
  CAS Google Scholar
• Projan, S. J. Why is big Pharma getting out of antibacterial drug discovery? Curr. Opin. Microbiol. 6, 427–430 (2003).
  Article PubMed Google Scholar
• Fernandes, P. Antibacterial discovery and development — the failure of success? Nature Biotechnol. 24, 1497–1503 (2006).
  Article CAS Google Scholar
• Talbot, G. H. et al. Bad bugs need drugs: an update on the development pipeline from the antimicrobial availability task force of the infectious diseases society of America. Clin. Infect. Dis. 42, 657–668 (2006).
  Article PubMed Google Scholar
• Blount, K. F., Wang, J. X., Lim, J., Sudarsan, N. & Breaker, R. R. Antibacterial lysine analogs that target lysine riboswitches. Nature Chem. Biol. 3, 44–49 (2007). Identified lysine analogues that bind to lysine riboswitches in vitro and inhibit the growth of Bacillus subtilis . Also discusses the general importance of riboswitches and their suitability as antibacterial drug targets.
  Article CAS Google Scholar
• Wright, G. D. The antibiotic resistome: the nexus of chemical and genetic diversity. Nature Rev. Microbiol. 5, 175–186 (2007).
  Article CAS Google Scholar
• Mwangi, M. M. et al. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc. Natl Acad. Sci. USA 104, 9451–9456 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Finlay, B. B. & Falkow, S. Common themes in microbial pathogenicity revisited. Microbiol. Mol. Biol. Rev. 61, 136–169 (1997).
  CAS PubMed PubMed Central Google Scholar
• Lee, Y. M., Almqvist, F. & Hultgren, S. J. Targeting virulence for antimicrobial chemotherapy. Curr. Opin. Pharmacol. 3, 513–519 (2003).
  Article CAS PubMed Google Scholar
• Marra, A. Can virulence factors be viable antibacterial targets? Expert Rev. Anti. Infect. Ther. 2, 61–72 (2004).
  Article CAS PubMed Google Scholar
• Savage, D. C. Microbial ecology of the gastrointestinal tract. Annu. Rev. Microbiol. 31, 107–133 (1977).
  Article CAS PubMed Google Scholar
• Backhed, F. et al. The gut microbiota as an environmental factor that regulates fat storage. Proc. Natl Acad. Sci. USA 101, 15718–15723 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Miller, J. F., Mekalanos, J. J. & Falkow, S. Coordinate regulation and sensory transduction in the control of bacterial virulence. Science 243, 916–922 (1989). A perspective that emphasizes the need to understand coordinate regulation and sensory transduction to understand the events that occur during the pathogenesis of infectious disease.
  Article CAS PubMed Google Scholar
• Virgin, H. W. In vivo veritas: pathogenesis of infection as it actually happens. Nature Immunol. 8, 1143–1147 (2007). An overview and perspective of the benefits that are ascribed to bridging the disciplines of microbiology and immunology, including lessons from Heisenberg.
  Article CAS Google Scholar
• Moxon, E. R., Rainey, P. B., Nowak, M. A. & Lenski, R. E. Adaptive evolution of highly mutable loci in pathogenic bacteria. Curr. Biol. 4, 24–33 (1994).
  Article CAS PubMed Google Scholar
• Monack, D. M., Mueller, A. & Falkow, S. Persistent bacterial infections: the interface of the pathogen and the host immune system. Nature Rev. Microbiol. 2, 747–765 (2004). Review and consideration of the dynamic cross-talk at the host–pathogen interface and the delicate balance between protective immunity and immunopathology.
  Article CAS Google Scholar
• Kaufmann, S. H. E. The contribution of immunology to the rational design of novel antibacterial vaccines. Nature Rev. Microbiol. 5, 491–504 (2007).
  Article CAS Google Scholar
• Kokai-Kun, J. F. & Mond, J. J. Antibody therapy for treatment or prevention of infectious diseases. Drug Discov. Today: Therapeutic Strategies 1, 475–481 (2004).
  CAS Google Scholar
• Pirofski, L. A. & Casadevall, A. Immunomodulators as an antimicrobial tool. Curr. Opin. Microbiol. 9, 489–495 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Hung, D. L. & Hultgren, S. J. Pilus biogenesis via the chaperone/usher pathway: an integration of structure and function. J. Struct. Biol. 124, 201–220 (1998).
  Article CAS PubMed Google Scholar
• Telford, J. L., Barocchi, M. le A., Margarit, I., Rappuoli, R. & Grandi, G. Pili in Gram-positive pathogens. Nature Rev. Microbiol. 4, 509–519 (2006).
  Article CAS Google Scholar
• Barocchi, M. A. et al. A pneumococcal pilus influences virulence and host inflammatory responses. Proc. Natl Acad. Sci. USA 103, 2857–2862 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Mulvey, M. A. Adhesion and entry of uropathogenic Escherichia coli. Cell. Microbiol. 4, 257–271 (2002).
  Article CAS PubMed Google Scholar
• Garofalo, C. K. et al. Escherichia coli from urine of female patients with urinary tract infections is competent for intracellular bacterial community formation. Infect. Immun. 75, 52–60 (2007).
  Article CAS PubMed Google Scholar
• Martinez, J. J., Mulvey, M. A., Schilling, J. D., Pinkner, J. S. & Hultgren, S. J. Type 1 pilus-mediated bacterial invasion of bladder epithelial cells. EMBO J. 19, 2803–2812 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Sauer, F. G., Mulvey, M. A., Schilling, J. D., Martinez, J. J. & Hultgren, S. J. Bacterial pili: molecular mechanisms of pathogenesis. Curr. Opin. Microbiol. 3, 65–72 (2000).
  Article CAS PubMed Google Scholar
• Anderson, G. G. et al. Intracellular bacterial biofilm-like pods in urinary tract infections. Science 301, 105–107 (2003).
  Article CAS PubMed Google Scholar
• Justice, S. S. et al. Differentiation and developmental pathways of uropathogenic Escherichia coli in urinary tract pathogenesis. Proc. Natl Acad. Sci. USA 101, 1333–1338 (2004). Revealed the multi-step E. coli pathogenic cascade using time-lapse fluorescence videomicroscopy to observe infected mouse-bladder explants.
  Article CAS PubMed PubMed Central Google Scholar
• Rosen Da, H. T., Stamm W. E., Humphrey, P. A. & Hultgren, S. J. Detection of intracellular bacterial communities in human urinary tract infection. PLoS Med. (in the press).
• Mulvey, M. A. et al. Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli. Science 282, 1494–1497 (1998).
  Article CAS PubMed Google Scholar
• Mysorekar, I. U. & Hultgren, S. J. Mechanisms of uropathogenic Escherichia coli persistence and eradication from the urinary tract. Proc. Natl Acad. Sci. USA 103, 14170–14175 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Wright, K. J., Seed, P. C. & Hultgren, S. J. Development of intracellular bacterial communities of uropathogenic Escherichia coli depends on type 1 pili. Cell. Microbiol. 9, 2230–2241 (2007).
  Article CAS PubMed Google Scholar
• Kihlberg, J. & Magnusson, G. Use of carbohydrates and peptides in studies of adhesion of pathogenic bacteria and in efforts to generate carbohydrate-specific T cells. Pure Appl. Chem. 68, 2119–2128 (1996).
  Article CAS Google Scholar
• Firon, N., Ashkenazi, S., Mirelman, D., Ofek, I. & Sharon, N. Aromatic alpha-glycosides of mannose are powerful inhibitors of the adherence of type 1 fimbriated Escherichia coli to yeast and intestinal epithelial cells. Infect. Immun. 55, 472–476 (1987).
  CAS PubMed PubMed Central Google Scholar
• Bouckaert, J. et al. Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin. Mol. Microbiol. 55, 441–455 (2005).
  Article CAS PubMed Google Scholar
• Sauer, F. G., Remaut, H., Hultgren, S. J. & Waksman, G. Fiber assembly by the chaperone–usher pathway. Biochim. Biophys. Acta 1694, 259–267 (2004).
  Article CAS PubMed Google Scholar
• Chen, S. L. et al. Identification of genes subject to positive selection in uropathogenic strains of Escherichia coli: a comparative genomics approach. Proc. Natl Acad. Sci. USA 103, 5977–5982 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Svensson, A. et al. Design and evaluation of pilicides: potential novel antibacterial agents directed against uropathogenic Escherichia coli. Chembiochem 2, 915–918 (2001).
  Article CAS PubMed Google Scholar
• Larsson, A. et al. Multivariate design, synthesis, and biological evaluation of peptide inhibitors of FimC/FimH protein–protein interactions in uropathogenic Escherichia coli. J. Med. Chem. 48, 935–945 (2005).
  Article CAS PubMed Google Scholar
• Pinkner, J. S. et al. Rationally designed small compounds inhibit pilus biogenesis in uropathogenic bacteria. Proc. Natl Acad. Sci. USA 103, 17897–17902 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Report No. 04–5512, 153–183 (US Government Printing Office, Washington DC, 2004).
• Report No. 04–5512, 187–209 (US Government Printing Office, Washington DC, 2004).
• Ronald, A. R. et al. Urinary tract infection in adults: research priorities and strategies. Int. J. Antimicrob. Agents 17, 343–348 (2001).
  Article CAS PubMed Google Scholar
• Acharya, V. N. Urinary tract infection — a dangerous and unrecognised forerunner of systemic sepsis. J. Postgrad. Med. 38, 52–54 (1992).
  CAS PubMed Google Scholar
• Schmitt, C. K., Meysick, K. C. & O'Brien, A. D. Bacterial toxins: friends or foes? Emerg. Infect. Dis. 5, 224–234 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Spangler, B. D. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol. Rev. 56, 622–647 (1992).
  CAS PubMed PubMed Central Google Scholar
• Hung, D. T., Shakhnovich, E. A., Pierson, E. & Mekalanos, J. J. Small-molecule inhibitor of Vibrio cholerae virulence and intestinal colonization. Science 310, 670–674 (2005).
  Article CAS PubMed Google Scholar
• Keller, M. A. & Stiehm, E. R. Passive immunity in prevention and treatment of infectious diseases. Clin. Microbiol. Rev. 13, 602–614 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Arnon, S. S., Schechter, R., Maslanka, S. E., Jewell, N. P. & Hatheway, C. L. Human botulism immune globulin for the treatment of infant botulism. N. Engl. J. Med. 354, 462–471 (2006).
  Article CAS PubMed Google Scholar
• Young, J. A. & Collier, R. J. Anthrax toxin: receptor binding, internalization, pore formation, and translocation. Annu. Rev. Biochem. 76, 243–265 (2007). Describes the structural basis and molecular mechanisms of the anthrax toxin and provides insight into toxin function.
  Article CAS PubMed Google Scholar
• Saenz, J. B., Doggett, T. A. & Haslam, D. B. Identification and characterization of small molecules that inhibit intracellular toxin transport. Infect. Immun. 75, 4552–4561 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Zhao, L. & Haslam, D. B. A quantitative and highly sensitive luciferase-based assay for bacterial toxins that inhibit protein synthesis. J. Med. Microbiol. 54, 1023–1030 (2005).
  Article CAS PubMed Google Scholar
• Tonello, F., Seveso, M., Marin, O., Mock, M. & Montecucco, C. Screening inhibitors of anthrax lethal factor. Nature 418, 386 (2002).
  Article CAS PubMed Google Scholar
• Panchal, R. G. et al. Identification of small molecule inhibitors of anthrax lethal factor. Nature Struct. Mol. Biol. 11, 67–72 (2004).
  Article CAS Google Scholar
• Turk, B. E. et al. The structural basis for substrate and inhibitor selectivity of the anthrax lethal factor. Nature Struct. Mol. Biol. 11, 60–66 (2004).
  Article CAS Google Scholar
• Russell, P. K. Project BioShield: what it is, why it is needed, and its accomplishments so far. Clin. Infect. Dis. 45, S68–S72 (2007).
  Article PubMed Google Scholar
• US Securities and Exchange Commission (SEC). Pharmathene, Inc. Form 10-Q, Quarter Ended September 30, Commission File Number 001-32587. SEC web site [online], (2007).
• Food and Drug Administration Center for Drug Evaluation and Research. Summary Minutes of the Anti-Infective Drugs Advisory Committee on April 12, 2007 [online], (2007).
• Gyles, C. L. Shiga toxin-producing Escherichia coli: an overview. J. Anim. Sci. 85, E45–E62 (2007).
  Article CAS PubMed Google Scholar
• Sandkvist, M. et al. General secretion pathway (eps) genes required for toxin secretion and outer membrane biogenesis in Vibrio cholerae. J. Bacteriol. 179, 6994–7003 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Cornelis, G. R. The type III secretion injectisome. Nature Rev. Microbiol. 4, 811–825 (2006).
  Article CAS Google Scholar
• Cornelis, G. R. & Wolf-Watz, H. The Yersinia Yop virulon: a bacterial system for subverting eukaryotic cells. Mol. Microbiol. 23, 861–867 (1997).
  Article CAS PubMed Google Scholar
• Cornelis, G. R. Yersinia type III secretion: send in the effectors. J. Cell. Biol. 158, 401–408 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Cornelis, G. R. & Van Gijsegem, F. Assembly and function of type III secretory systems. Annu. Rev. Microbiol. 54, 735–774 (2000).
  Article CAS PubMed Google Scholar
• Rosqvist, R., Hakansson, S., Forsberg, A. & Wolf-Watz, H. Functional conservation of the secretion and translocation machinery for virulence proteins of yersiniae, salmonellae and shigellae. EMBO J. 14, 4187–4195 (1995).
  Article CAS PubMed PubMed Central Google Scholar
• Kauppi, A. M., Nordfelth, R., Uvell, H., Wolf-Watz, H. & Elofsson, M. Targeting bacterial virulence: inhibitors of type III secretion in Yersinia. Chem. Biol. 10, 241–249 (2003).
  Article CAS PubMed Google Scholar
• Nordfelth, R., Kauppi, A. M., Norberg, H. A., Wolf-Watz, H. & Elofsson, M. Small-molecule inhibitors specifically targeting type III secretion. Infect. Immun. 73, 3104–3114 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Wolf, K. et al. Treatment of Chlamydia trachomatis with a small molecule inhibitor of the Yersinia type III secretion system disrupts progression of the chlamydial developmental cycle. Mol. Microbiol. 61, 1543–1555 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Muschiol, S. et al. A small-molecule inhibitor of type III secretion inhibits different stages of the infectious cycle of Chlamydia trachomatis. Proc. Natl Acad. Sci. USA 103, 14566–14571 (2006). An elegant application of chemical genetics to microbial pathogenesis. A small molecule that was identified as a T3SS inhibitor in Yersinia spp. inhibited virulence of C. trachomatis , which supports the notion that the T3SS is important in C. trachomatis pathogenesis.
  Article CAS PubMed PubMed Central Google Scholar
• Bailey, L. et al. Small molecule inhibitors of type III secretion in Yersinia block the Chlamydia pneumoniae infection cycle. FEBS Lett. 581, 587–595 (2007).
  Article CAS PubMed Google Scholar
• Saye, D. E. Recurring and antimicrobial-resistant infections: considering the potential role of biofilms in clinical practice. Ostomy Wound Manage. 53, 46–62 (2007).
  PubMed Google Scholar
• Hall-Stoodley, L. et al. Direct detection of bacterial biofilms on the middle-ear mucosa of children with chronic otitis media. JAMA 296, 202–211 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Carron, M. A., Tran, V. R., Sugawa, C. & Coticchia, J. M. Identification of Helicobacter pylori biofilms in human gastric mucosa. J. Gastrointest. Surg. 10, 712–717 (2006).
  Article PubMed Google Scholar
• Lam, J., Chan, R., Lam, K. & Costerton, J. W. Production of mucoid microcolonies by Pseudomonas aeruginosa within infected lungs in cystic fibrosis. Infect. Immun. 28, 546–556 (1980).
  CAS PubMed PubMed Central Google Scholar
• Singh, P. K. et al. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 407, 762–764 (2000).
  Article CAS PubMed Google Scholar
• Benghezal, M. et al. Inhibitors of bacterial virulence identified in a surrogate host model. Cell. Microbiol. 9, 1336–1342 (2007).
  Article CAS PubMed Google Scholar
• Keller, L. & Surette, M. G. Communication in bacteria: an ecological and evolutionary perspective. Nature Rev. Microbiol. 4, 249–258 (2006). A holistic perspective of the potential roles of QS signals, from a cooperative to the battleground.
  Article CAS Google Scholar
• Bassler, B. L. & Losick, R. Bacterially speaking. Cell 125, 237–246 (2006). A creative composition and a lively review of the business of bacterial communication.
  Article CAS PubMed Google Scholar
• Kjelleberg, S. et al. Do marine natural products interfere with prokaryotic AHL regulatory systems? Aquat. Microb. Ecol. 13, 85–93 (1997).
  Article Google Scholar
• Manefield, M. et al. Evidence that halogenated furanones from Delisea pulchra inhibit acylated homoserine lactone (AHL)-mediated gene expression by displacing the AHL signal from its receptor protein [in process citation]. Microbiology 145, 283–291 (1999).
  Article CAS PubMed Google Scholar
• Higgins, D. A. et al. The major Vibrio cholerae autoinducer and its role in virulence factor production. Nature 14 Nov 2007 (doi:10.1038/nature06284).
  Article CAS PubMed Google Scholar
• Hentzer, M. et al. Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. EMBO J. 22, 3803–3815 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Bjarnsholt, T. & Givskov, M. Quorum-sensing blockade as a strategy for enhancing host defences against bacterial pathogens. Phil. Trans. R. Soc. Lond. B 362, 1213–1222 (2007).
  Article CAS Google Scholar
• Geske, G. D., O'Neill, J. C. & Blackwell, H. E. _N_-phenylacetanoyl-L-homoserine lactones can strongly antagonize or superagonize quorum sensing in Vibrio fischeri. ACS Chem. Biol. 2, 315–319 (2007). Identified a non-native N -acylated- L -homoserine lactone that can either inhibit or strongly induce QS in the marine symbiont V. fischeri , depending on the molecule concentration.
  Article CAS PubMed PubMed Central Google Scholar
• Miller, M. B., Skorupski, K., Lenz, D. H., Taylor, R. K. & Bassler, B. L. Parallel quorum sensing systems converge to regulate virulence in Vibrio cholerae. Cell 110, 303–314 (2002). Revealed the redundant QS capacity in V. cholerae and discusses implications in terms of V. choler ae pathogenicity.
  Article CAS PubMed Google Scholar
• Wadhams, G. H. & Armitage, J. P. Making sense of it all: bacterial chemotaxis. Nature Rev. Mol. Cell Biol. 5, 1024–1037 (2004).
  Article CAS Google Scholar
• Galperin, M. Y. Structural classification of bacterial response regulators: diversity of output domains and domain combinations. J. Bacteriol. 188, 4169–4182 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Ulrich, L. E. & Zhulin, I. B. MiST: a microbial signal transduction database. Nucleic Acids Res. 35, D386–D390 (2007).
  Article CAS PubMed Google Scholar
• Mascher, T., Helmann, J. D. & Unden, G. Stimulus perception in bacterial signal-transducing histidine kinases. Microbiol. Mol. Biol. Rev. 70, 910–938 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Barrett, J. F. & Hoch, J. A. Two-component signal transduction as a target for microbial anti-infective therapy. Antimicrob. Agents Chemother. 42, 1529–1536 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Mayville, P. et al. Structure-activity analysis of synthetic autoinducing thiolactone peptides from Staphylococcus aureus responsible for virulence. Proc. Natl Acad. Sci. USA 96, 1218–1223 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Otto, M. Quorum-sensing control in Staphylococci — a target for antimicrobial drug therapy? FEMS Microbiol. Lett. 241, 135–141 (2004).
  Article CAS PubMed Google Scholar
• Arthur, M., Molinas, C. & Courvalin, P. The VanS–VanR two-component regulatory system controls synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147. J. Bacteriol. 174, 2582–2591 (1992).
  Article CAS PubMed PubMed Central Google Scholar
• Evers, S. & Courvalin, P. Regulation of VanB-type vancomycin resistance gene expression by the VanS(B)–VanR (B) two-component regulatory system in Enterococcus faecalis V583. J. Bacteriol. 178, 1302–1309 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Sintchenko, V., Iredell, J. R. & Gilbert, G. L. Pathogen profiling for disease management and surveillance. Nature Rev. Microbiol. 5, 464–470 (2007).
  Article CAS Google Scholar
• Payne, D. J., Gwynn, M. N., Holmes, D. J. & Pompliano, D. L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nature Rev. Drug Discov. 6, 29–40 (2007).
  Article CAS Google Scholar
• Jones, C. H. et al. FimH adhesin of type 1 pili is assembled into a fibrillar tip structure in the Enterobacteriaceae. Proc. Natl Acad. Sci. USA 92, 2081–2085 (1995).
  Article CAS PubMed PubMed Central Google Scholar